AC/LCNC 5-year survival rates in the most recent series reported in the literature
| Author [Reference] . | AC (n) . | AC 5-year survival . | LCNC (n) . | LCNC 5-year survival . | Year . |
|---|---|---|---|---|---|
| Garcia-Yuste et al. [9] | 43 | 72% (all stages) | 22 | 21% (all stages) | 2000 |
| Iyoda et al. [13] | – | – | 50 | 35.3% (Stage I) | 2001 |
| Filosso et al. [17] | 44 | 77% (all stages) | – | – | 2002 |
| Battafarano et al. [15] | – | – | 82 | 30.3% (all stages) | 2005 |
| Rossi et al. [18] | – | – | 83 | 27.6% (all stages) | 2005 |
| Asamura et al. [11] | 9 | 77.8% (all stages) | 141 | 40.3% (all stages) | 2006 |
| Veronesi et al. [14] | – | – | 144 | 52% (Stage I) | 2006 |
| Present series | 126 | 82% (Stage I) | 135 | 48% (Stage I) | 2013 |
| Author [Reference] . | AC (n) . | AC 5-year survival . | LCNC (n) . | LCNC 5-year survival . | Year . |
|---|---|---|---|---|---|
| Garcia-Yuste et al. [9] | 43 | 72% (all stages) | 22 | 21% (all stages) | 2000 |
| Iyoda et al. [13] | – | – | 50 | 35.3% (Stage I) | 2001 |
| Filosso et al. [17] | 44 | 77% (all stages) | – | – | 2002 |
| Battafarano et al. [15] | – | – | 82 | 30.3% (all stages) | 2005 |
| Rossi et al. [18] | – | – | 83 | 27.6% (all stages) | 2005 |
| Asamura et al. [11] | 9 | 77.8% (all stages) | 141 | 40.3% (all stages) | 2006 |
| Veronesi et al. [14] | – | – | 144 | 52% (Stage I) | 2006 |
| Present series | 126 | 82% (Stage I) | 135 | 48% (Stage I) | 2013 |
AC: atypical carcinoid; LCNC: large-cell neuroendocrine carcinoma.
AC/LCNC 5-year survival rates in the most recent series reported in the literature
| Author [Reference] . | AC (n) . | AC 5-year survival . | LCNC (n) . | LCNC 5-year survival . | Year . |
|---|---|---|---|---|---|
| Garcia-Yuste et al. [9] | 43 | 72% (all stages) | 22 | 21% (all stages) | 2000 |
| Iyoda et al. [13] | – | – | 50 | 35.3% (Stage I) | 2001 |
| Filosso et al. [17] | 44 | 77% (all stages) | – | – | 2002 |
| Battafarano et al. [15] | – | – | 82 | 30.3% (all stages) | 2005 |
| Rossi et al. [18] | – | – | 83 | 27.6% (all stages) | 2005 |
| Asamura et al. [11] | 9 | 77.8% (all stages) | 141 | 40.3% (all stages) | 2006 |
| Veronesi et al. [14] | – | – | 144 | 52% (Stage I) | 2006 |
| Present series | 126 | 82% (Stage I) | 135 | 48% (Stage I) | 2013 |
| Author [Reference] . | AC (n) . | AC 5-year survival . | LCNC (n) . | LCNC 5-year survival . | Year . |
|---|---|---|---|---|---|
| Garcia-Yuste et al. [9] | 43 | 72% (all stages) | 22 | 21% (all stages) | 2000 |
| Iyoda et al. [13] | – | – | 50 | 35.3% (Stage I) | 2001 |
| Filosso et al. [17] | 44 | 77% (all stages) | – | – | 2002 |
| Battafarano et al. [15] | – | – | 82 | 30.3% (all stages) | 2005 |
| Rossi et al. [18] | – | – | 83 | 27.6% (all stages) | 2005 |
| Asamura et al. [11] | 9 | 77.8% (all stages) | 141 | 40.3% (all stages) | 2006 |
| Veronesi et al. [14] | – | – | 144 | 52% (Stage I) | 2006 |
| Present series | 126 | 82% (Stage I) | 135 | 48% (Stage I) | 2013 |
AC: atypical carcinoid; LCNC: large-cell neuroendocrine carcinoma.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
